Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a transformative fourth quarter, with a key regulatory milestone and important data readouts expected by year-end.
The company has one marketed drug, Korlym, used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or cannot have surgery. The drug, which received FDA approval in February 2012, has experienced significant revenue growth since its launch, increasing from $3.31 million in 2012 to $482.4 million in 2023.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.